A new series of carbapenems, having a saturated or partially unsaturated heterocycle at C-2, has been synthesised. The in vitro antibacterial activity of these compounds and their stability to human dehydropeptidase-1 (DHP-1) are described. The stereochemistry of the C-2 side-chain and the presence of a double bond in the heterocycle were shown to have significant effects on the stabilities of the compoundsto DHP-1.
with a jS-methyl group2) has resulted in compounds that combine chemical and metabolic stability with enhanced antibacterial potency, as exemplified by meropenem (2) 3).
Directly linked aryl groups at C-2 have also been shown to improve stability to DHP-14).
Our recent interests have focused on identifying a carbapenem suitable for the treatment of community acquired infections and which is also stable to the DHP-1 enzyme. Herein we report the chemistry and biological properties of a range of novel C-2 heterocyclic carbapenems.
Chemi stry A range of non-aromatic ketones (3)5) was synthesised as precursors to the novel C-2 substituents and converted to the corresponding silylenol ethers (4) by trapping the enolates with^-butyldimethylsilyl triflate6) (Scheme 1). DEC. 1996 Lewis acid mediated condensation of these silylenol ethers (4a~f) with the 4-acetoxyazetidinone (5)7) gave the C-4 functionalised azetidinones (6a~f) following Ndesilylation. Elaboration to the bicyclic carbapenem was achieved using established intramolecular Wittig cyclisation methodology8). Acid mediated desilylation of the C-8 hydroxyl group and subsequent palladium (O) catalysed cleavage of the allyl esters (8a~f) yielded the C-2 heterocyclic carbapenems (9a~f) (Scheme 2).
Diastereoisomers
of the tetrahydrothiophen-2-yl and 2,3-dihydrobenzofuran-2-yl derivatives were separated after coupling to the azetidinone (5). Their stereochemistries were assigned by comparison with the NMR spectra of the tetrahydofuran-2-yl analogues (6a) and (6b) which were prepared from chiral ketones (3a) and (3b)5'.
Incorporation of a jS-methyl group at the C-l position of the carbapenemnucleus has been reported to improve the stability of compounds to the DHP-1 enzyme2). Hence, the 1/J-methyl C-2 tetrahydrofuran-2-yl carScheme 1. Synthesis of sililenol ethers.
bapenems (12a) and (12b) were synthesised in order to compare them with their C-l unsubstituted counterparts (9a) and (9b). Treatment of the pyridyl thioester (10)9) with the lithium organocuprate species (13) gave the tetrahydrofuran ketone (ll) (Scheme 3). This was converted to the carbapenem diastereoisorners (12a) and (12b) using the Wittig methodology previously described (Scheme 3) .
Carbapenems incorporating a partially unsaturated heterocycle at C-2 presented a greater synthetic challenge. Reaction of C-4 acetoxyazetidinone (5) with 1- (2? 5-dihydrothiophen-3-yl) l -(^-butyldimethylsilyloxy)-ethene (4g) afforded only a poor yield of the desired C-4 alkylation product (6g). The major product, was the Diels Alder adduct (14), analogous to products described with m-chloroperoxybenzoic acid gave the corresponding sulphone (17b). Subsequent removal of the protecting groups provided the carbapenem (18b).
Unsaturated substituents can also be introduced directly at C-2 via carbon-carbon bond formation1 1}. Thus, the dihydropyranyl and dihydrothiopyranyl analogues (20a) and (20b) were synthesised using palladium catalysed cross-coupling reactions between the requisite heterocyclic stannane and the enol triflate derived from the readily available /Mceto ester (19)12). Triphenylarsine proved to be a versatile ligand for these transformations13). Deprotection of the^-nitrobenzyl esters (20a) and (20b) was achieved without double bond reduction using zinc in THF/phosphate buffer14) to afford carbapenems (21a) and (21b) (Scheme 4).
Biological Evaluation
The antibacterial activities and susceptibilities to human DHP-1 of these new carbapenems in comparison with values for imipenem and meropenemare reported in Table 1 . Compoundswere evaluated in vitro against a range of important target organisms associated with community acquired infections.
In general, the novel C-2 heterocyclic carbapenems were highly potent against the target organisms. They exhibited useful Gram-negative antibacterial activity and good activity against Gram-positive organisms.
The stereochemistry of the C-2 heterocycle was found to impart a significant effect on the stability of the compound to DHP-1. The C-2 tetrahydrofuran-2-yl (9a) and (9b), tetrahydrothiophen-2-yl (9c) and (9d) and 2,3-dihydrobenzofuran-2-yl derivatives (9e) and (9f) all exhibited the same relationship between stereochemistry and relative DHP-1 stability, the (S) diastereoisomer being the more stable. Molecular modelling studies on the tetrahydrothiophen-2-yl diastereoisomers (9c) and (9d) indicated that the (S) isomer tended to favour conformations with the bulk of the tetrahydrothiophene ring on the /?-face of the carbapenem nucleus. In contrast, the less stable (R) isomer favoured conformations with the bulk of the ring on the a-face. This is in agreement with the observation that a jS-methyl group at the Cl position can lead to increased stability2). Interestingly, no increase in stability to observed by the introduction of a l/?-methyl group to the C-2 tetrahydrofuran-2-yl compounds, (12a) and (12b). Although this is in contrast to results reported for thienamycin2), it is in accord with literature reports that the incorporation of a l/?-methyl group does not necessarily always result in improved DHP-1 stability1 5). However, as in the 1-unsubstituted series, one diastereoisomer was considerably more stable than the other.
The presence of a double bond conjugated to the carbapenem (18a, 18b, 21a and 21b) resulted in compounds exhibiting reasonable stabilities to DHP-1 hydrolysis, albeit less stable than meropenem (2).
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In conclusion, the novel C-2 heterocyclic carbapenems described herein exhibited good antibacterial activity, especially against Gram-positive organisms. Of the diastereoisomers, the (S)-isomer was considerably more stable to DHP-1 than the (i^)-isomer. Introduction of a double bond into the heterocycle also improved DHP-1 stability. However, none of the carbapenems achieved the level of stability to DHP-1 exhibited by meropenem (2) .
Experimental IR spectra were recorded in CH2C12solution unless otherwise specified and were recorded on Perkin Elmer 983 or Philips PU9706 spectrometers. UVspectra were recorded on a Beckman DU spectrophotometer in EtOH solution. NMRspectra were recorded on a Bruker AC250 spectrometer in the solvents specified. Mass spectral data were recorded on a VGZAB1For a VGTrio-2 spectrometer in electron impact (El), chemical ionisation using NH3 gas (CI), electrospray (ESI-MS) or fast atom bombardment (FAB) mode, as specified.
Chromatography was performed on Merck silica 60, <230 or 230~400 mesh. Salts were purified using Dianion HP-20SS resin.
(4e and 4f)
/-Butyldimethylsilyl trifluoromethanesulphonate (6. 58 ml, 28.64mmol) in dichloromethane (5ml) was added dropwise to a solution of (i?5f)-2-acetyl-2,3-dihydrobenzofuran (3e) and (3f) Compounds 4a, 4b, 4c, 4d and 4g were prepared using a similar procedure.
A solution of (4e) and (4f) (6.28g, 22.75mmol) in dichloromethane (50ml) was added to a solution of
ethyl]-l-trimethylsilyl-2-azetidinone (5)7) (7.5 g, 20.89 mmol) in dichloromethane (100 ml). To this mixture was 1261 added a solution of zinc chloride (21 ml ofa 1 M solution in diethylether, 21.0mmol) dropwise over 10 minutes.
After stirring for 16 hours at room temperature, the mixture was diluted with dichloromethane and washed successively with water, saturated aqueous sodium hydrogen carbonate and brine. The solution was dried over magnesiumsulphate and the solvent evaporated in vacuo to yield a yellow gum. The gum was dissolved in tetrahydrofuran (100ml) and water (10ml) Compounds 6a, 6b, 6c, 6d and 6g were prepared using a similar procedure.
Allyl glyoxylate (770mg, 5.83mmol) in benzene (30 ml) was heated at reflux for 1 hour using Dean and Stark apparatus. Thesolution was cooled to roomtemperature and treated with (6e) (2.05 g, 5.27mmol). The mixture was stirred for 16 hours at room temperature, concentrated and then purified by chromatography on silica gel eluting with 20 and 30% ethyl acetate in hexane to 
The crude chloro compoundwas dissolved in dioxan (12ml) and treated with triphenylphosphine (2.51 g, 9.58mmol) at room temperature. The solution was concentrated to approximately half of its volume and was then treated with 2,6-lutidine (309ml, 2.65 mmol).
After stirring for 3.5 hours the mixture was diluted with ethyl acetate, washed successively with 5%aqueous citric acid, brine, saturated aqueous sodium hydrogen carbonate solution and brine, dried over magnesium sulphate and then concentrated in vacuo. The residue was purified by chromatography on silica gel eluting with ethyl acetate to yield allyl 2- Compounds 7a, 7b, 7c, 7d, 7f and 7g were prepared using a similar procedure. Fractions containing the product (HPLCanalysis) were combined, concentrated and freeze-dried to give the title compound (9e) (132mg, 70%); UV Amax (H2O)nm (s) 276 (8463) Compounds 9a, 9b, 9c, 9d and 9f were prepared using a similar procedure. The spectral data for 9a, 9b, 9c, 9d and 9f are listed in Table 2 .
A solution of (2-tetrahydrofuranyl)tri-«-butylstannane16) (3.94 g, 10.9 mmol) under argon, and cooled to -70°C. The mixture was stirred in the cold for 4.5 hours. Saturated aqueous ammoniumchloride solution (30 ml) was then added by syringe, and the mixture was then poured into ethyl acetate (250 ml)/saturated aqueous ammoniumchloride solution (100 ml). After separation the aqueous layer was re-extracted with ethyl acetate (3 x 75 ml). The combined organic layers were dried over magnesium sulphate, Preparation of compounds12a and 12b was carried out by a method similar to that described for 9e. The isomers were separated by chromatography on silica gel after conversion to the w-tributylphoshorane. The spectral data for 12a and 12b are listed in Table 2 .
(15) (340mg, 0.46mmol) (prepared using an analogous method to that of 7e except that 4-methoxybenzyl glyoxylate was used instead of allyl glyoxylate) in dichloromethane (15 ml) was cooled to 0°C and treated with trimethylsilyl chloride (140ml, 1.10mmol) and triethylamine (154ml, 1.10mmol).
After stirring for 1 hour at 0°C, the reaction mixture was diluted with ethyl acetate, washed successively with dilute aqueous sodium hydrogen carbonate and brine, dried over magnesium sulphate and the solvent evaporated to yield the crude title compound (16) (370mg, 97%); IR vmax (CH2C12) cm "1 2961, 1737, 1668, 1630, 1612, 1514, 1374and 1174; MS m/z (El) 691 (M+), (CI, +ve ion, ammonia) 692
A solution of the crude phosphorane (16) (350mg, 0.51 mmol) in toluene (100ml) was heated at reflux for 1 hour. The reaction mixture was cooled, concentrated and the residue purified by chromatography on silica gel eluting with 10 and 20% ethyl acetate in hexane yielding the title compound (17a) (125mg, 52%); IR vmax (CH2C12) cm "1 2960, 1779, 1718, 1612, 1516, 1302 and 1174 ; *H NMR (CDC13) 5 0.12 (9H, s), 1.27 (3H, d, /=6.2Hz), m), 3.13 (1H, dd, /=6.6, 2.9Hz), m), 3.80 (3H, s), m), 5.20 (2H, s), 5.99 (1H, m), 6.88 (2H, d, /=8.7Hz Compound18b was prepared using a similar procedure. The spectral data for compound18b is listed in Table 2 . (1.05 /d, 0.62mmol ). The triflate solution was then allowed to stir with cooling for 30 minutes. Triphenylarsine (18mg, 0.059mmol) was added to a solution of tris(dibenzylideneacetone)palladium (0) (26 mg, 0.028 mmol) in THF (3 ml). After stirring for 5 minutes the catalyst was added to the crude triflate solution at -70°C (rinsed in with THF (2ml)). Zinc chloride (1.15 ml, 1 m in ether, 1.15mmol) and solid anhydrous lithium chloride (49mg, 1.15mmol) were then added followed by 4-trimethyl-stannyl-5,6-dihydo-2H-pyran5) (1 54 mg, 0.62 mmol) in THF (7 ml). The cooling bath was removed and the reaction mixture stirred for 2 hours. Concentration and chromatography on silica gel eluting with 70% Compound20b was prepared using a similar procedure.
A suspension of 4-nitrobenzyl (57?,6S)-2-(5,6-dihydro-2H-pyran-4-yl)-6-[(7?)-hydroxyethyl]carbapen-2-em-3-carboxylate (20a) (138mg, 0.33mmol) in THF-0.35m phosphate buffer (1 :3, pH 6) (5ml) was treated with activated zinc (1.4 g ) and the mixture rapidly stirred for 30 minutes. The mixture was filtered through celite and the residue thorougly washed with water. After adjusting the pH of the filtrate to pH 6.5 it was washed with ethyl acetate and concentrated to approximately 10ml. The crude solution was chromatographed on HP20SSeluting with water then 1 -10% THF in water to afford the title compound (21a) (28mg, 28%); UV Amax (H2O) Compound21b was prepared using a similar procedure. The spectral data for 21b is listed in Table 2 MOPSat pH 7.0) (0.08ml) was challenged with either human kidney homogenate or pure human DHP-1 enzyme* (0.08 ml of2.5 /^g/ml solution) at 37°C. Samples were removed at 0, 30, 60, and 90 minute time points and analysed by reverse phase HPLC. The hydrolysis of the carbapenem was monitored by integration of the area under the peak for the test compound. The results were submitted to a statistical evaluation programme which allowed for the calculation of the percentage of test compoundremaining intact after 60 minutes. Control experiments were conducted for each test compound to check its stability in buffer alone.
